Findings

What do systematic reviews say?

6 questions · 6 findings · 3 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 33.3%Low 2 · 33.3%Moderate 2 · 33.3%High 0 · 0%

Autologous myeloablative selective HSCT vs cyclophosphamide

Serious adverse events · people with systemic sclerosis

Autologous myeloablative selective HSCT showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
RR 1.43 [0.99, 2.08]
1 study · 71 participants
Moderate

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Serious adverse events · people with systemic sclerosis

Autologous non‐myeloablative selective HSCT probably leads to higher serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
RR 1.7 [1.2, 2.3]
1 study · 156 participants
Moderate

Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide

Serious adverse events · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

Carvedilol vs beta‐blocker

Serious adverse events · adults with cirrhosis and gastroesophageal varices

Carvedilol showed no clear difference in serious adverse events compared with traditional, non‐selective beta‐blockers (low certainty).

1 finding from 1 review

Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices 2018 · Cochrane Headline outcomes only
RR 0.97 [0.67, 1.42]
10 studies · 810 participants
Low

Carvedilol vs beta‐blocker

Non‐serious adverse events · adults with cirrhosis and gastroesophageal varices

It is very uncertain whether carvedilol changes non‐serious adverse events compared with traditional, non‐selective beta‐blockers (very low certainty).

1 finding from 1 review

Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices 2018 · Cochrane Headline outcomes only
RR 0.55 [0.23, 1.29]
6 studies · 596 participants
Very low

Intervention not reported

Serious adverse events · Patients with fibromyalgia

It is very uncertain whether the intervention changes serious adverse events (very low certainty).

1 finding from 1 review

Selective serotonin reuptake inhibitors for fibromyalgia syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 168 participants
Very low